In this context, chemokine stromal cell-derived factor-1 (CXCL12) and its receptor CXCR4 have been considered as potential therapeutic targets in epithelial ovarian cancer [119], as the in vitro and in vivo blocking (i.e., AMD3100, selective CXCR4 antagonist) of the CXCR4/CXCL12 axis inhibited ovarian cancer progression, by reducing tumor cell proliferation, migration and invasion [119,120]. The gene discussed is CXCR4; the disease is ovarian carcinoma.